Treatment of refractory ascites

Praveena G. Velamati, H. Franklin Herlong

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

In 1996, the International Ascites CLub defined "refractory ascites" as ascites that cannot be mobilized by medical therapy or that recurs early after initial mobilization despite continued treatment. Of all patients with ascites, 5% to 10% will become refractory to medical therapy. Management of refractory ascites should attempt to control fluid accumulation, reduce the likelihood of developing complications such as spontaneous bacterial peritonitis (SBP) and the hepatorenal syndrome, and improve the patient's nutritional status and overall well-being. Measures to control ascites accumulation include documenting medication and dietary compliance and eliminating potentially nephrotoxic agents that promote sodium retention. Large volume paracentesis is an effective first step in managing these patients and can be performed routinely in an outpatient setting. When more than 5 L of fluid are removed during a paracentesis, intravenous albumin should be infused to reduce the likelihood of the patient developing postparacentesis circulatory dysfunction. Transjugular intrahepatic portosystemic shunt (TIPS) placement effectively eliminates ascites; however, there is no convincing evidence that the shunt improves mortality. Furthermore, it is associated with frequent complications of encephalopathy and shunt malfunction. We feel TIPS should be reserved for patients requiring extremely frequent paracentesis, those who develop significant postparacentesis circulatory dysfunction, or those with hepatic hydrothorax. Patients who have evidence of SBP should be treated with antibiotics and intravenous albumin infusion. Patients who have had a previous episode of SBP or an ascitic fluid protein level of Less than 1.0 should receive prophylactic antibiotics. Overall, the prognosis for patients with refractory ascites remains grim, and Liver transplantation is the only definitive therapy. Appropriate candidates should be identified promptly and referred for transplant evaluation.

Original languageEnglish (US)
Pages (from-to)530-537
Number of pages8
JournalCurrent Treatment Options in Gastroenterology
Volume9
Issue number6
DOIs
StatePublished - Dec 1 2006
Externally publishedYes

Fingerprint

Ascites
Paracentesis
Peritonitis
Transjugular Intrahepatic Portasystemic Shunt
Therapeutics
Albumins
Hydrothorax
Hepatorenal Syndrome
Anti-Bacterial Agents
Medication Adherence
Ascitic Fluid
Brain Diseases
Nutritional Status
Intravenous Infusions
Liver Transplantation
Outpatients
Sodium
Transplants
Mortality
Liver

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Treatment of refractory ascites. / Velamati, Praveena G.; Herlong, H. Franklin.

In: Current Treatment Options in Gastroenterology, Vol. 9, No. 6, 01.12.2006, p. 530-537.

Research output: Contribution to journalReview article

Velamati, Praveena G. ; Herlong, H. Franklin. / Treatment of refractory ascites. In: Current Treatment Options in Gastroenterology. 2006 ; Vol. 9, No. 6. pp. 530-537.
@article{36ab632cfb9f43ae9d34a6dbceb7c165,
title = "Treatment of refractory ascites",
abstract = "In 1996, the International Ascites CLub defined {"}refractory ascites{"} as ascites that cannot be mobilized by medical therapy or that recurs early after initial mobilization despite continued treatment. Of all patients with ascites, 5{\%} to 10{\%} will become refractory to medical therapy. Management of refractory ascites should attempt to control fluid accumulation, reduce the likelihood of developing complications such as spontaneous bacterial peritonitis (SBP) and the hepatorenal syndrome, and improve the patient's nutritional status and overall well-being. Measures to control ascites accumulation include documenting medication and dietary compliance and eliminating potentially nephrotoxic agents that promote sodium retention. Large volume paracentesis is an effective first step in managing these patients and can be performed routinely in an outpatient setting. When more than 5 L of fluid are removed during a paracentesis, intravenous albumin should be infused to reduce the likelihood of the patient developing postparacentesis circulatory dysfunction. Transjugular intrahepatic portosystemic shunt (TIPS) placement effectively eliminates ascites; however, there is no convincing evidence that the shunt improves mortality. Furthermore, it is associated with frequent complications of encephalopathy and shunt malfunction. We feel TIPS should be reserved for patients requiring extremely frequent paracentesis, those who develop significant postparacentesis circulatory dysfunction, or those with hepatic hydrothorax. Patients who have evidence of SBP should be treated with antibiotics and intravenous albumin infusion. Patients who have had a previous episode of SBP or an ascitic fluid protein level of Less than 1.0 should receive prophylactic antibiotics. Overall, the prognosis for patients with refractory ascites remains grim, and Liver transplantation is the only definitive therapy. Appropriate candidates should be identified promptly and referred for transplant evaluation.",
author = "Velamati, {Praveena G.} and Herlong, {H. Franklin}",
year = "2006",
month = "12",
day = "1",
doi = "10.1007/s11938-006-0009-4",
language = "English (US)",
volume = "9",
pages = "530--537",
journal = "Current Treatment Options in Gastroenterology",
issn = "1092-8472",
publisher = "Current Science, Inc.",
number = "6",

}

TY - JOUR

T1 - Treatment of refractory ascites

AU - Velamati, Praveena G.

AU - Herlong, H. Franklin

PY - 2006/12/1

Y1 - 2006/12/1

N2 - In 1996, the International Ascites CLub defined "refractory ascites" as ascites that cannot be mobilized by medical therapy or that recurs early after initial mobilization despite continued treatment. Of all patients with ascites, 5% to 10% will become refractory to medical therapy. Management of refractory ascites should attempt to control fluid accumulation, reduce the likelihood of developing complications such as spontaneous bacterial peritonitis (SBP) and the hepatorenal syndrome, and improve the patient's nutritional status and overall well-being. Measures to control ascites accumulation include documenting medication and dietary compliance and eliminating potentially nephrotoxic agents that promote sodium retention. Large volume paracentesis is an effective first step in managing these patients and can be performed routinely in an outpatient setting. When more than 5 L of fluid are removed during a paracentesis, intravenous albumin should be infused to reduce the likelihood of the patient developing postparacentesis circulatory dysfunction. Transjugular intrahepatic portosystemic shunt (TIPS) placement effectively eliminates ascites; however, there is no convincing evidence that the shunt improves mortality. Furthermore, it is associated with frequent complications of encephalopathy and shunt malfunction. We feel TIPS should be reserved for patients requiring extremely frequent paracentesis, those who develop significant postparacentesis circulatory dysfunction, or those with hepatic hydrothorax. Patients who have evidence of SBP should be treated with antibiotics and intravenous albumin infusion. Patients who have had a previous episode of SBP or an ascitic fluid protein level of Less than 1.0 should receive prophylactic antibiotics. Overall, the prognosis for patients with refractory ascites remains grim, and Liver transplantation is the only definitive therapy. Appropriate candidates should be identified promptly and referred for transplant evaluation.

AB - In 1996, the International Ascites CLub defined "refractory ascites" as ascites that cannot be mobilized by medical therapy or that recurs early after initial mobilization despite continued treatment. Of all patients with ascites, 5% to 10% will become refractory to medical therapy. Management of refractory ascites should attempt to control fluid accumulation, reduce the likelihood of developing complications such as spontaneous bacterial peritonitis (SBP) and the hepatorenal syndrome, and improve the patient's nutritional status and overall well-being. Measures to control ascites accumulation include documenting medication and dietary compliance and eliminating potentially nephrotoxic agents that promote sodium retention. Large volume paracentesis is an effective first step in managing these patients and can be performed routinely in an outpatient setting. When more than 5 L of fluid are removed during a paracentesis, intravenous albumin should be infused to reduce the likelihood of the patient developing postparacentesis circulatory dysfunction. Transjugular intrahepatic portosystemic shunt (TIPS) placement effectively eliminates ascites; however, there is no convincing evidence that the shunt improves mortality. Furthermore, it is associated with frequent complications of encephalopathy and shunt malfunction. We feel TIPS should be reserved for patients requiring extremely frequent paracentesis, those who develop significant postparacentesis circulatory dysfunction, or those with hepatic hydrothorax. Patients who have evidence of SBP should be treated with antibiotics and intravenous albumin infusion. Patients who have had a previous episode of SBP or an ascitic fluid protein level of Less than 1.0 should receive prophylactic antibiotics. Overall, the prognosis for patients with refractory ascites remains grim, and Liver transplantation is the only definitive therapy. Appropriate candidates should be identified promptly and referred for transplant evaluation.

UR - http://www.scopus.com/inward/record.url?scp=33751312301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751312301&partnerID=8YFLogxK

U2 - 10.1007/s11938-006-0009-4

DO - 10.1007/s11938-006-0009-4

M3 - Review article

C2 - 17081486

AN - SCOPUS:33751312301

VL - 9

SP - 530

EP - 537

JO - Current Treatment Options in Gastroenterology

JF - Current Treatment Options in Gastroenterology

SN - 1092-8472

IS - 6

ER -